Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 48, 1348-1349, March 1, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duffy, M. J.
Right arrow Articles by Lijnen, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duffy, M. J.
Right arrow Articles by Lijnen, H. R.

Tissue-type Plasminogen Activator, a New Prognostic Marker in Breast Cancer

M. J. Duffy1, P. O'Grady, D. Devaney, L. O'Siorain, J. J. Fennelly and H. R. Lijnen

Departments of Nuclear Medicine [M. J. D., P. O'G., L. O'S.], Pathology [D. D.] and Medical Oncology [J. J. F.], St. Vincent's Hospital, Dublin 4, Ireland; and the Center for Thrombosis and Vascular Research, University of Louvain, Louvain, Belgium [H. R. L.]

Plasminogen activator is a protease existing in two forms known as tissue-type and urokinase-type plasminogen activator. In this investigation, patients with breast cancers containing high levels of the tissue-type enzyme had a significantly longer disease-free interval and survival compared with patients with low levels of the enzyme. For the disease-free interval, the effect of tissue-type plasminogen activator was independent of tumor stage, grade, axillary node involvement, and estradiol receptor status. It is concluded that tissue-type plasminogen activator is a new prognostic marker in breast cancer.

1 To whom requests for reprints should be addressed, at Nuclear Medicine Department, St. Vincent's Hospital, Dublin 4, Ireland.

Received 8/ 3/87. Revised 10/29/87. Accepted 11/18/87.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. Harkonen, S. Torn, R. Kurkela, K. Porvari, A. Pulkka, A. Lindfors, V. Isomaa, and P. Vihko
Sex Hormone Metabolism in Prostate Cancer Cells during Transition to an Androgen-Independent State
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 705 - 712.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. O. Chappuis, B. Dieterich, V. Sciretta, C. Lohse, H. Bonnefoi, S. Remadi, and A.-P. Sappino
Functional Evaluation of Plasmin Formation in Primary Breast Cancer
J. Clin. Oncol., May 15, 2001; 19(10): 2731 - 2738.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1988 by the American Association for Cancer Research.